Guide ALD n°30 « Cancer de l’œsophage »

Objectives

Provide an evidence-informed national care pathway to optimise diagnosis, treatment, supportive care and follow-up for adults covered by France’s long-term condition scheme for oesophageal cancer. The guide, developed from clinical recommendations, consensus and expert opinion where evidence is limited, aims to support treating physicians while retaining individual clinical responsibility and adaptation to comorbidities and local protocols.[1][2]

• Improve early recognition and diagnostic confirmation through upper gastrointestinal endoscopy, multiple biopsies and pathological examination, with repeat biopsies where uncertainty or persistent symptoms remain.[3][4]
• Assess tumour extent, histological type, comorbidities, nutritional condition, functional status and treatment feasibility before deciding management.[4][5][6]
• Deliver stage-adapted care, including endoscopic treatment for selected superficial lesions, surgery as the reference treatment for localised disease, combined treatment for selected locally advanced disease, and palliative chemotherapy or symptom-focused interventions for metastatic disease.[6][7][8]
• Strengthen patient-centred decisions by agreeing treatment with the patient and treating doctor after multidisciplinary review, explaining expected benefits and adverse effects, and documenting the plan in an individualised care programme.[6]
• Protect quality of life by addressing dysphagia, nutrition, pain, psychological and social needs, treatment toxicity, patient education, autonomy and adherence throughout the pathway.[9][10][11]
• Detect recurrence, second primary cancers and late effects through coordinated long-term surveillance, while supporting smoking and alcohol cessation, social support and return to employment where relevant.[12][13][14]

Implementation

Implement care through authorised specialist cancer teams working closely with general practitioners, community professionals and the patient’s support network. Delivery combines multidisciplinary decision-making, documented personalised care plans, hospital and ambulatory supportive care, structured clinical surveillance, and regulatory oversight of medicines and treatment protocols.[15][16][17][18]

• Develop and maintain the guide through joint work by the Haute Autorité de Santé and the Institut national du cancer, using a multidisciplinary working group, review group and Haute Autorité de Santé methodology; involve professional societies, patient representatives, health-insurance schemes and clinical and administrative contributors.[2][19][20]
• Provide treatment in establishments authorised by the regional health agency for cancer surgery, radiotherapy, chemotherapy and other medical cancer treatment, subject to minimum activity, quality and technical criteria.[15][16]
• Coordinate diagnostic and therapeutic proposals through multidisciplinary consultation meetings, except where an approved pathway applies directly or urgent treatment is needed; incorporate the meeting report into the electronic medical record and send it to the general practitioner.[16][17]
• Issue a personalised care programme covering care stages and treatment timing, and ensure the specialist promptly shares the plan, multidisciplinary report, pathology report and discharge summary with the general practitioner.[15][17]
• Undertake pre-treatment assessment with thoraco-abdominal computed tomography as the principal staging investigation, complemented by endoscopic ultrasound, positron emission tomography-computed tomography, cervical imaging, tracheobronchial endoscopy, laparoscopy or other tests according to clinical circumstances.[4][5]
• Assess nutritional, biological, cardiac and pulmonary status before treatment, provide nutritional support before gastrointestinal surgery, offer tobacco and alcohol cessation support where appropriate, and undertake geriatric assessment for people aged 75 years or over before multidisciplinary review.[21][5][6]
• Deliver supportive care in hospital, outpatient and home settings, including psychological and social support, pain management, nutrition, physiotherapy, fatigue management, rehabilitation, hospital-at-home services and palliative-care networks as needed.[22][17]
• Provide therapeutic patient education from diagnosis or another suitable illness stage, based on assessed needs, jointly agreed objectives, planned individual or group sessions and review of daily-life implementation.[11]
• Monitor treatment safety through clinical and laboratory review before chemotherapy cycles and at least weekly radiotherapy review, including nutritional status, blood counts, renal and hepatic function, weight loss, skin effects and treatment tolerance.[22]
• Organise follow-up primarily through specialist teams in liaison with the general practitioner during the first five years, with subsequent arrangements tailored to the patient, specialised team and clinical situation.[12][13]
• Use clinical examination, upper endoscopy, thoraco-abdominal computed tomography and annual ear, nose and throat assessment to identify recurrence, late complications and second cancers; apply more intensive endoscopic surveillance after endoscopic treatment of superficial lesions.[23]
• Maintain lifelong follow-up for squamous-cell oesophageal cancer because of second-cancer risk associated with alcohol and tobacco exposure, and at least five years for adenocarcinoma.[13][23]
• Review the medical guides every three years and update the List of Procedures and Services at least annually between major revisions.[1]

The material does not specify a dedicated implementation budget, treatment-cost schedule, funding gap, resource-mobilisation plan or formal national performance-indicator framework. It identifies clinical follow-up, authorisation criteria, multidisciplinary documentation and periodic guide revision as the principal quality and accountability mechanisms described.[1][15][16]

Monitoring & Evaluation

Monitoring centres on clinically coordinated surveillance throughout treatment and survivorship, complemented by periodic review of the guidance and quality controls for authorised cancer services. The material does not establish a unified document-level performance framework, numerical targets, national reporting schedule or formal audit system.[1][15][16]

• Review the HAS and INCa medical guides every three years, and update the List of Procedures and Services at least annually between major revisions through the HAS and INCa websites.[1]
• Use multidisciplinary consultation records, individualised care plans and personalised care programmes as accountability and communication mechanisms, incorporating relevant reports into the electronic medical record and routinely transmitting them to the general practitioner.[6][16][17]
• Assure service quality through regional health-agency authorisation of cancer-treatment establishments, minimum annual activity thresholds, cross-cutting quality provisions and treatment-specific technical criteria.[16]
• Assess clinical status before each chemotherapy cycle, including treatment tolerance, nutritional status, blood count, renal and hepatic function, blood pressure, skin condition and the venous access site.[22]
• Review patients receiving radiotherapy at least weekly, with particular attention to general condition, weight loss and skin effects.[22]
• Reassess analgesic effectiveness and adverse effects promptly, ideally within 48 hours, so that pain treatment can be adjusted.[24]
• Monitor early and late complications of surgery, radiotherapy and chemotherapy, including pulmonary and infectious complications, digestive toxicity, malnutrition, haematological abnormalities, cardiac effects, neuropathy, renal toxicity and venous thrombosis.[9][25][10]
• Use computed tomography after preoperative radiochemotherapy to detect metastatic progression that could preclude surgery, and do not use tumour markers to measure treatment response.[9]
• Organise follow-up to identify recurrence, second primary cancers, late effects, nutritional needs, quality-of-life concerns and social or occupational support needs.[12][13][15]
• Provide lifelong surveillance for squamous-cell oesophageal cancer because of the risk of second cancer, and at least five years of follow-up for adenocarcinoma.[13][23]
• Schedule clinical examinations every three months for the first two years, every six months for the next five years and annually thereafter; the schedule reflects working-group opinion because high-level evidence was unavailable.[23][26]
• Undertake thoraco-abdominal computed tomography three months after exclusive radiotherapy or chemotherapy and every six months for two years, then according to symptoms; after surgery with residual oesophagus, undertake imaging at six months and thereafter according to symptoms.[23]
• Conduct annual ear, nose and throat assessments to detect second cancers, and use selective bronchial endoscopy according to symptoms rather than routinely.[23]
• Intensify endoscopic surveillance after endoscopic treatment of superficial lesions, with endoscopy at three months, every six months for two years and annually thereafter; otherwise tailor endoscopy to symptoms, treatment, specialist judgement and patient views.[23]
• Advise patients to seek review for weight loss, abdominal pain, dysphagia, bone pain, cough, breathlessness or voice changes, and refer suspected recurrence to the original or another specialist team for multidisciplinary decision-making.[26]
• Recognise stage-specific five-year relative survival figures as contextual outcome data: 37% for localised disease, 18% for locoregional disease, 3% for metastatic disease and 11% for undetermined stage.[27]

Clinical follow-up is principally specialist-led in liaison with the general practitioner during the first five years, with potential transition to general-practitioner-led follow-up thereafter under an arrangement agreed with the specialist team and patient.[12][13]Quantitative implementation indicators, mandatory reporting requirements, population surveillance arrangements and formal accountability measures beyond authorisation, clinical documentation and care coordination are not specified.[21][17][28]

Costing & Financing

No budget, treatment price, programme allocation, financing source, funding gap, resource-mobilisation plan or economic assumption is specified for the guideline or its recommended care pathway.[1][9][17]

• Recognise that the guide applies to patients covered by the French long-term condition scheme, but no reimbursement value or expenditure estimate is provided.[2]
• Note that good-use guidance addresses reimbursed medicines supplied in addition to hospital services and may identify authorised or temporarily acceptable off-label uses, without providing financial amounts.[18]
• Use authorised establishments and specialised multidisciplinary teams for surgery, radiotherapy, chemotherapy and other cancer treatments, but the source provides no associated staffing, equipment or service-cost estimates.[15][16]
• Interpret the reported 11,475 patients covered for this disease under the general social-security scheme at 31 December 2009 as an administrative count rather than a budget or cost figure.[2]

The material identifies resource-intensive elements such as specialist follow-up, imaging, endoscopy, multidisciplinary review, nutritional support, rehabilitation, home hospitalisation and palliative-care services, but does not quantify their costs, capacity requirements or funding arrangements.[22][9][23]